Abstract: The present disclosure relates to a method and system for providing a virtual storage pool set for a target application by receiving performance requirements associated with the target application; and providing a virtual storage pool set for the target application according to the performance requirements and on the basis of storage capabilities of physical storage resources, the virtual storage pool set comprising one or more virtual storage pools. By means of various embodiments of the present disclosure, virtual storage pools can be provided for the target application efficiently and flexibly and can be adjusted dynamically.

Abstract: Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.

Abstract: Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.